Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Telo Genomics Corp V.TELO

Alternate Symbol(s):  TDSGF

Telo Genomics Corp. is a biotech company pioneering the telomere platform in the industry with applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. The Company's lead application, TELO-MM is being developed to provide actionable information to medical professionals in the treatment of multiple myeloma, a form of blood cancer. Its clinical studies and product development design includes TeloView SMM, TeloView Test to Predict Patient Resistance to Treatment, development in collaboration with the Mayo Clinic and TeloView Test to monitor minimal residual disease in MM patients. The Company, by combining quantitative analysis of three-dimensional telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, is developing products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers.


TSXV:TELO - Post by User

Bullboard Posts
Comment by STOCKMAN70on Nov 19, 2017 8:58pm
95 Views
Post# 26993565

RE:RE:RE:RE:RE:Stay Away

RE:RE:RE:RE:RE:Stay Away Good post Jamming, but I would disagree with the comment that the pool of money is small.  Seems like most financings have been oversold lately.  There is a lot of money looking for deals but smart investors are looking for the whole package when they invest - product, management, industry, use of funds raised, past performance etc...quite possible that some of those are lacking here and personally I don't like to see management blame share price on shareholder's - it is managment's job to show why the stock is undervalued if they believe it is.  I would rather see management take responsibility for past mistakes and the current share price and their inabiliy to raise funds. If you look at the financials you can see much of the funds raised in the past were not put to good use (and this doesn't even include share based payments).

I would feel a lot better about investing here if management stepped up and said we made mistakes, we realize that and have learned that we should do X instead of Y going forward.  The reduction in burn rate is a start but they need a lot more money before the tech is ready for the market (and the HL market is small; the prostrate market is huge but that's a long ways off).  I hope that Dr. Mai has a good advisor as she owns a huge piece of this company and if she is just going with what this managment team tells her the advice is obviously biased.

GLTA
Bullboard Posts